Prescription Furosemide Tablets Recalled for Foreign Substance Contamination
Graviti Pharmaceuticals recalls Furosemide 40 mg tablets nationwide. Affected lot FUB125042G (expires 05/13/2027) contains a foreign substance. Patients taking this medication should contact their pharmacist or doctor immediately.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This Class II recall involves actual contamination (foreign substance) in a prescription medication, representing a risk-of-harm product. No illnesses or injuries have been reported in the source material.
Plain-English summary
Graviti Pharmaceuticals Private Limited is recalling Furosemide 40 mg tablets nationwide due to the presence of a foreign substance in affected bottles. The product is manufactured by Graviti Pharmaceuticals and distributed under the Rising Pharmaceuticals brand.
The recall encompasses approximately 4,212 bottles in the affected lot (FUB125042G, expiration date 05/13/2027), with NDC 64980-563-10. Distribution was nationwide throughout the United States.
Patients currently taking Furosemide from this lot should contact their pharmacist or healthcare provider immediately without discontinuing the medication on their own. Consumers should verify their medication lot number against FUB125042G and request guidance on next steps, including potential alternative treatments.
The recalled product
- Product
- FUROSEMIDE (FUROSEMIDE)
- Brand
- FUROSEMIDE
- Manufacturer
- Graviti Pharmaceuticals Private Limited
- Category
- Drug
- Hazard
- foreign-substance
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot# FUB125042G
- Exp. 05/13/2027
UPCs (1)
- 0364980564014
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · FUROSEMIDE
- ModerateFurosemide tablets recalled for presence of N-nitroso impurity
FDA (Drugs) · 2026-04-29
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27